Global Out-Licensing and Royalty Monetization of TLM-001, a Treatment for Meibomian Gland Dysfunction
First written in FY2022. 7 of 11 entries say "Advanced", first in FY2026-H1. Latest entry: 2026-09-11.
The whole theme swung hardest in 2021: 1 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The clinical trial conducted by Maruho progressed to an early Phase 2 clinical trial during the current fiscal year, and we received a milestone payment.」
TLM-001 progressed to an early Phase 2 trial conducted by Maruho, generating milestone revenue under the agreement. - FY2026-H1AdvancedAnnual report
「Maruho Co., Ltd. completed the Phase 1 clinical trial of TLM-001, an eye ointment for meibomian gland dysfunction associated with dry eye, and made significant progress into the Phase 2 clinical trial. We are receiving milestone revenue under the long-term agreement.」
TLM-001 completed the Phase 1 clinical trial conducted by Maruho and progressed to Phase 2, generating milestone revenue under the long-term agreement. - FY2024RestatedAnnual report
「We are currently developing an eye ointment primarily based on a vitamin D-related substance and have already entered into an agreement with Maruho Co., Ltd. for global out-licensing. Under the agreement, we will receive milestone revenue as development progresses and royalty revenue once the product is launched.」
For TLM-001, the company has reconfirmed the global out-licensing to Maruho and the revenue model tied to development progress and post-launch commercialization. - FY2023RestatedAnnual report
「We are currently developing an eye ointment primarily based on a vitamin D-related substance and have already entered into an agreement with Maruho Co., Ltd. for global out-licensing.」
For TLM-001, the global out-licensing model involving milestone revenue tied to development progress and royalty revenue after commercialization has been reiterated. - FY2022First statedAnnual report
「We are currently developing an eye ointment primarily based on a vitamin D-related substance and have already entered into an agreement with Maruho Co., Ltd. for global out-licensing. Under the agreement, we will receive milestone revenue as development progresses and royalty revenue once the product is launched.」
The development and global out-licensing of the eye ointment are linked to development-based revenue and post-launch royalties.